Literature DB >> 2536515

Abnormalities in lymphocyte profile and specificity repertoire of patients with Waldenstrom's macroglobulinemia, multiple myeloma, and IgM monoclonal gammopathy of undetermined significance.

L M Pilarski1, E J Andrews, H M Serra, J A Ledbetter, B A Ruether, M J Mant.   

Abstract

The characteristics of T and B lymphocyte profile and B lymphocyte specificity repertoire were compared in patients with Waldenstrom's macroglobulinemia (WM), IgM monoclonal gammopathy of undetermined significance (IgM MGUS), multiple myeloma (MM), and age-matched normal subjects. Patients with MM had both significantly reduced frequency and number of sIg+ (surface Ig) B cells, whereas patients with WM and IgM MGUS had a reduced frequency but normal numbers of sIg+ B cells in circulation as detected in a capping assay. WM was distinguished by the large numbers of cells in the peripheral blood lymphocyte (PBL) pool that expressed CD9 (BA-2) and CD24 (BA-1) and were monoclonal, based on light chain analysis using flow cytometry. The profile of T lineage cells showed that the ratio of CD4:CD8 was significantly reduced in both MM and WM due to a reduction in the CD4 set. The CD4+ cells were qualitatively abnormal as well, with an enriched proportion of the 4B4+ (CDw29) subset and decreased proportion of the Lp220+ (CD45R) subset. This appeared to be an effect of the disease process on the relatively immature Lp220+ set. From clonal analysis, those patients with WM or IgM MGUS (unlike MM patients) did not exhibit enhanced reactivity with auto-Ig determinants, and most WM patients (7/8) and half of the IgM MGUS patients (3/6) did not have enriched proportions of B cells reactive to tetanus toxoid (TT). The TT-specific B cells in both WM and IgM MGUS, in contrast to MM, appeared fully functional in secretion of anti-TT IgM in vivo. We speculate that the more severe immunodeficiency in MM may be controlled or exacerbated by the presence of an anti-Ig network. The absence of this network in WM allows a relatively more effective immune response, but the immunodeficiency that is observed in these patients involves some abnormality in normal lymphocyte differentiation (is also present in MM).

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2536515     DOI: 10.1002/ajh.2830300202

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  5 in total

1.  The structure of two IgMs showing different activity from a patient with Waldenstrom's macroglobulinaemia.

Authors:  E Méndez; C Osuna; A Sánchez; Y Revilla; F Soriano; C Montalbán; J Seguí; J Avila
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

2.  IgM-enriched human intravenous immunoglobulin suppresses T lymphocyte functions in vitro and delays the activation of T lymphocytes in hu-SCID mice.

Authors:  T Vassilev; N Mihaylova; E Voynova; M Nikolova; M Kazatchkine; S Kaveri
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

3.  Poor Correlation between Pneumococcal IgG and IgM Titers and Opsonophagocytic Activity in Vaccinated Patients with Multiple Myeloma and Waldenstrom's Macroglobulinemia.

Authors:  Johanna Karlsson; Lucy Roalfe; Harriet Hogevik; Marta Zancolli; Björn Andréasson; David Goldblatt; Christine Wennerås
Journal:  Clin Vaccine Immunol       Date:  2016-04-04

4.  Comparative study of immune status to infectious agents in elderly patients with multiple myeloma, Waldenstrom's macroglobulinemia, and monoclonal gammopathy of undetermined significance.

Authors:  Johanna Karlsson; Björn Andréasson; Nahid Kondori; Evelina Erman; Kristian Riesbeck; Harriet Hogevik; Christine Wennerås
Journal:  Clin Vaccine Immunol       Date:  2011-04-20

5.  The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma.

Authors:  K Giannopoulos; W Kaminska; I Hus; A Dmoszynska
Journal:  Br J Cancer       Date:  2012-01-05       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.